The US FDA has approved the drug Mitapivat, marketed as Aqvesme, as the very first oral therapy for anemia in adults with ...

The US FDA has approved mitapivat, the first oral medicine for treating anemia caused by thalassemia. At present, mitapivat ...

An oral pyruvate kinase (PK) activator, mitapivat becomes the only approved option for treating anemia in both ...

The US FDA has greenlit Mitapivat, the first oral treatment for anaemia in adults with thalassemia, marking a significant advancement in thalassemia care.

Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment ...

The US Food and Drug Administrations (FDA) approval of the first-ever oral pill for anaemia in adults with thalassemia marks a historic milestone and can be a game changer in the management of the ...

Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

FDA approves Agios' Aqvesme for anemia in alpha and beta thalassemia, backed by Phase 3 data and a REMS safety program.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In a small study ...

The thalassemias are an inherited group of heterogeneous anemias in which 1 or more of the globin chains in the hemoglobin tetramer are absent. Among the 4 classic alpha thalassemia syndromes, there ...

Iron deficiency anemia (IDA) and thalassemia represent two of the most prevalent causes of microcytic anemia worldwide. Effective screening is critical not only to guide appropriate treatment — as IDA ...

On the auspicious occasion of the New Year, the Thalassemia & Sickle Cell Society (TSCS) extends its warmest wishes for a ...